TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01616979

Intervention type: PROCEDURE
Intervention: placing saline bag during cardiac displacement
Description: For grafting to LCX territory, the heart is displaced using positioner and a suction-type epicardial stabiliser is applied to the target area. The degree of cardiac displacement and the LV compression by stabilisers are adjusted for maximal surgical access and minimal haemodynamic instability.
Study: NCT01930760

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Medical Training Educational
Description: Educational is modeled on the Theory of Planned Action, which proposes that unless people believe that their actions can have an effect on the desired outcome they have little incentive to act or persevere in the face of difficulties. Based on this theory we will be providing physicians with information on how to calculate, plot and track BMI and how this can be associated with identification of overweight children before they present with symptoms of obesity. This intervention will attempt to demonstrate that BMI calculating, plotting and tracking are useful diagnostic monitoring tools and that their actions may lead to more effective prevention and/or treatment.~The education intervention will not prescribe specific discussion initiation tools, although the participants will not be prevented from independently changing their communication behaviour.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing behavioural
Description: The behavioural intervention will incorporate specific Motivational Interviewing (MI) tools and information from a previously completed qualitative study with obese children (Obadia et al.). This study generated suggestions of how physicians can encourage children to think positively about making changes towards a healthier body weight. This intervention is designed to address physicians' lack of self-efficacy in communicating with children and their families about achieving a healthy body weight, and therefore would likely benefit from the input from children and the patient-centred theme of MI. It is based on the Trans-Theoretical Model and Stages of Change which postulates that people follow a step-wise progression towards change with specific constructs that need to be addressed before moving to the next step. These constructs are integral to the principles of MI
Study: NCT04761744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Study treatment consists of nivolumab 3mg/kg, and will be repeated every 2 weeks.
Study: NCT02795312

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Cessation Program
Description: Participants will take part in a 9-week Smoking Cessation Program
Study: NCT04539860

Intervention type: DEVICE
Intervention: Transdermal Optical Imaging
Description: Blood pressure measurements completed by standard assessment methods and Transdermal Optical Imaging
Study: NCT05757921

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Perisolv (A)
Description: Intended for cleaning periodontal pockets for both periodontitis and peri-implantitis. Softens degenerative tissue and biofilm before depuration of periodontal pockets. Does not affect healthy tissue.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard (B)
Description: Deepened periodontal pockets to be treated are performed by subgingivally debridement. This is performed with piezoelectric ultrasound (EMS) under rinsing water and subgingival debridement with hand instrument.
Study: NCT04124614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Description: Up to 3 mg pill

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: Up to 150 mg pill

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: Up to 150 mg pill

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Pill

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pill
Study: NCT03296631

Intervention type: OTHER
Intervention: collection of diapers with fresh stools
Description: collection of diapers with fresh stools
Study: NCT01166061

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Solution resembling active solution but without peptides

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Solution resembling active solution but without peptides

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Solution resembling active solution but without peptides

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Solution resembling active solution but without peptides

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Solution resembling active solution but without peptides

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ToleroMune Grass
Description: 1 x4 administrations 4 weeks apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ToleroMune Grass
Description: 1 x4 administrations 4 weeks apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ToleroMune Grass
Description: 1 x4 administrations 4 weeks apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ToleroMune Grass
Description: 1 x4 administrations 4 weeks apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ToleroMune Grass
Description: 1 x4 administrations 4 weeks apart
Study: NCT05840692

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Escitalopram 20 mg
Description: Antidepressant

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study: NCT01591863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fidaxomicin
Description: 6 months-5 years 11 months: oral suspension, 32 mg/kg/day with a maximum dose of 400 mg/day, divided into two doses, every 12 hours for 10 days.~6 years-17 years 11 months: tablets, 200 mg every 12 hours for 10 days.
Study: NCT00699218

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Stimulator Rapid2 made by Magstim Company Ltd. U.K.
Description: High frequency repetitive TMS given daily on weekdays for 3 weeks
Study: NCT00848341

Intervention type: DEVICE
Intervention: GUIDANT ICD SYSTEM
Study: NCT01479946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Electrochemotherapy
Description: bleomycin together with electroporation
Study: NCT01495520

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranolazine
Description: os, pill, 750 mg, b.i.d., 30 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: os, pill, b.i.d., 30 days
Study: NCT00424190

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Vancomycin plus IV Aztreonam
Description: vancomycin at 1 g parenteral infused over 60 minutes followed by aztreonam 1 g infused over 60 minutes, every 12 hours, for 5 to 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftaroline
Description: 600 mg parenteral infused over 60 minutes, every 12 hours for 5 to 14 days
Study: NCT02492256

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary vein isolation
Description: CARTO- reconstruction LA, preferably during same rhythm as SUMO map (generally sinus rhythm) for use during registration of SUMO map in CARTO. Conventional PVI by circumferential antral ablation according to standard procedures. Exit and Entrance block conformation. Attempt to induce sustained atrial tachycardia. Optional mapping and ablation of post-ablation atrial tachycardia.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GP ablation guided by SUMO technology
Description: CARTO- reconstruction LA, preferably during same rhythm as SUMO map (generally sinus rhythm) for use during registration of SUMO map in CARTO. High frequency stimulation (HFS; 20-Hz frequency, 5-ms pulse duration, and 15-mA output) to access positive vagal response (the heart rate decreasing by 50% at baseline). RF Ablation of SUMO hotspots (in sinus rhythm if AF converts)~• Target a region of 1.0-1.5 cm diameter around the SUMO 'hotspot'. Control HFS. Attempt to induce sustained atrial tachycardia. Optional mapping and ablation of post-ablation atrial tachycardia.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ILR implantation
Description: Implantation the ECG loop recorder according to standard procedure

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ILR implantation
Description: Implantation the ECG loop recorder according to standard procedure
Study: NCT00668590

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient video decision aid & telephone coaching
Description: The decision aid is a 30 minute video program that educates patients about their role in diabetes care. Telephone coaching will assist patients in initiating behavior change.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Printed educational brochure
Description: The printed brochure is an educational brochure developed by the NIH.
Study: NCT03396055

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: specific rehabilitation exercise
Description: specific rehabilitation exercise for patients with cervical myelopathy
Study: NCT04319744

Intervention type: OTHER
Intervention: other
Description: Our hypothesis is that playing video games may have positive effects on videostile use, but there is no research on this subject Our goal is to compare the performances of anesthesia assistants who have played video games with those who did not.

Intervention type: OTHER
Intervention: other
Description: Our hypothesis is that playing video games may have positive effects on videostile use, but there is no research on this subject Our goal is to compare the performances of anesthesia assistants who have played video games with those who did not.
Study: NCT04316156

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Uincare Homeplus
Description: Interactive digital healthcare system

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brochure
Description: Brochure
Study: NCT02495688

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Regional anesthesia
Description: Standard supraclavicular brachial plexus nerve block. Ultrasound-assisted. By an anesthesiologist. A mix of short- and medium lasting local anesthetics will be used.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia
Description: Standard procedure.
Study: NCT01195688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 638683 or placebo
Description: oral doses given to 6 subjects per dose group

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo solution
Description: oral doses given to 2 subjects per dose group
Study: NCT03082014

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: blood pressure lowering agent - dihydropyridine Ca2+-channel blocker

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: blood pressure lowering agent - dihydropyridine Ca2+-channel blocker

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: blood pressure lowering agent - dihydropyridine Ca2+-channel blocker

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Description: blood pressure lowering agent - angiotensin-receptor blockers

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Description: blood pressure lowering agent - angiotensin-receptor blockers

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Description: blood pressure lowering agent - angiotensin-receptor blockers

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atenolol
Description: blood pressure lowering agent - beta-blocker
Study: NCT00928733

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gastroduodenoscopy- Intraduodenal intubation
Description: 20 g ethanol diluted up to 10% in tap water

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gastroduodenoscopy- Intraduodenal intubation
Description: 20 g ethanol diluted up to 10% in tap water
Study: NCT03960164

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Dermal regeneration photosynthetic matrix (DRPM)
Description: Primary Procedure: DRPM implantation~1. Wound bed preparation and cleaning.~2. DRPM implantation.~3. Illumination with LED device.~Secondary Procedure: Autologous partial skin graft
Study: NCT02648867

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Maternal Feedback
Description: The PushCoach device consists of a modification of the standard fetal scalp electrode and a separate apparatus designed to detect movement of the fetal head by detecting movement of an FSE. The PushCoach will be attached to the patient by an adhesive pad over the sacrum and extend between the patient's legs approximately 2-3 inches from the vaginal introitus. It assesses the movement of the FSE attached to the fetal scalp during pushing. The amount of fetal movement will be measured and recorded. The PushCoach device is connected to a laptop computer which will provide optical and auditory feedback to the patient about descent of the fetal head with maternal expulsive efforts.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Maternal Feedback
Description: The PushCoach device consists of a modification of the standard fetal scalp electrode and a separate apparatus designed to detect movement of the fetal head by detecting movement of an FSE. The PushCoach will be attached to the patient by an adhesive pad over the sacrum and extend between the patient's legs approximately 2-3 inches from the vaginal introitus. It assesses the movement of the FSE attached to the fetal scalp during pushing. The amount of fetal movement will be measured and recorded. The PushCoach device is connected to a laptop computer which will provide optical and auditory feedback to the patient about descent of the fetal head with maternal expulsive efforts.
Study: NCT01236131

Intervention type: OTHER
Intervention: no intervention
Description: Not Applicable- no intervention
Study: NCT03082014

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atenolol
Description: blood pressure lowering agent - beta-blocker

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atenolol
Description: blood pressure lowering agent - beta-blocker
Study: NCT01910870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 25 mg/m² I.V. (day 1 to day 3) Total dose : 75 mg/m² every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronomic Cyclophosphamide
Description: 150 mg per os from day 1 to day 14 (total dose = 2100 mg) every 3 weeks
Study: NCT02221154

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inofolic®
Study: NCT00882193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betaine
Description: Betaine 20 gm/day in 2 divided doses for 48 weeks
Study: NCT02221154

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gonadotropins; Folic Acid
Description: standard ovarian stimulation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gonadotropins; Folic Acid
Description: standard ovarian stimulation
Study: NCT02546960

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ExPEC4V (4 : 4 : 4 : 4)
Description: Participants will receive single vaccination of ExPEC4V dose (4 : 4 : 4 : 4) as an intramuscular (i.m) injection into deltoid muscle in part 1 (age groups \>=18 to \<50 years and \>=50 years) and part 2 (based on review of safety data by the IDMC). The ExPEC4V doses contain polysaccharide antigen (in microgram \[mcg\]) from the ExPEC serotypes O1A, O2, O6A, and O25B.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ExPEC4V (4 : 4 : 4 : 8)
Description: Participants will receive single vaccination of ExPEC4V dose (4 : 4 : 4 : 8) as an i.m injection into deltoid muscle in part 1 (age groups \>=18 to \<50 years and \>=50 years) and part 2 (based on review of safety data by the IDMC). The ExPEC4V doses contain polysaccharide antigen (in mcg) from the ExPEC serotypes O1A, O2, O6A, and O25B.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ExPEC4V (8 : 8 : 8 : 8)
Description: Participants will receive single vaccination of ExPEC4V dose (8 : 8 : 8 : 8) as an i.m injection into deltoid muscle in part 1 (age groups \>=18 to \<50 years and \>=50 years) and part 2 (based on review of safety data by the IDMC). The ExPEC4V doses contain polysaccharide antigen (in mcg) from the ExPEC serotypes O1A, O2, O6A, and O25B.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ExPEC4V (8 : 8 : 8 : 16)
Description: Participants will receive single vaccination of ExPEC4V dose (8 : 8 : 8 : 16) as an i.m injection into deltoid muscle in part 1 (age groups \>=18 to \<50 years and \>=50 years) and part 2 (based on review of safety data by the IDMC). The ExPEC4V doses contain polysaccharide antigen (in mcg) from the ExPEC serotypes O1A, O2, O6A, and O25B.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ExPEC4V (16 : 16 : 16 : 16)
Description: Participants will receive single vaccination of ExPEC4V dose (16 : 16 : 16 : 16) as an i.m injection into deltoid muscle in part 1 (age groups \>=18 to \<50 years and \>=50 years) and part 2 (based on review of safety data by the IDMC). The ExPEC4V doses contain polysaccharide antigen (in mcg) from the ExPEC serotypes O1A, O2, O6A, and O25B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo (Tris-buffered saline) to ExPEC4V.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo (Tris-buffered saline) to ExPEC4V.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo (Tris-buffered saline) to ExPEC4V.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo (Tris-buffered saline) to ExPEC4V.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo (Tris-buffered saline) to ExPEC4V.
Study: NCT00392652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral microencapsulated diindolylmethane
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral microencapsulated diindolylmethane
Description: Given PO
Study: NCT02254902

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity intervention
Description: The Physical Activity intervention is a 3-month group-based program based on an efficacious physical activity intervention that has been culturally adapted for use with adult Somali women. The program targets increased physical activity through educational and experiential opportunities.
Study: NCT02546960

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo (Tris-buffered saline) to ExPEC4V.
Study: NCT00473603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lipid/heparin infusion
Description: to perform an i.v. lipid heparin infusion infusion for 4 h

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: lipid/heparin infusion
Description: to perform an i.v. lipid heparin infusion infusion for 4 h
Study: NCT04869033

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Farinelli's Breathing Exercise
Description: after 1 minute of normal breathing, follow this instruction; inhale 2 seconds, suspend 2 seconds, exhale 2 seconds. inhale 3 seconds, suspend 3 seconds, exhale 3 seconds. inhale 4 seconds, suspend 4 seconds, exhale 4 seconds. inhale 5 seconds, suspend 5 seconds, exhale 5 seconds. inhale 6 seconds, suspend 6 seconds, exhale 6 seconds. This cycle lasted 1 minute (60 seconds), called Farinelli's breathing (FB). When participants finished these cycle, repeated it again 4 times. 1 minute of NB + 4 minutes of FB called 1 set. The participants were asked to practice 6 sets/day, 5 days/week (Monday-Friday) for week 1-4, and increased duration to 8 sets/day, 5 days/week for week 5-8.

Intervention type: OTHER
Group type: OTHER
Intervention: Diaphragmatic Breathing Exercise
Description: after 1 minute of normal breathing, inhale 2 seconds and exhale 2 seconds with nasal airway. Continued breathing this pattern until 4 minutes, then back to normal breathing 1 minute . 1 minute of NB + 4 minute of DB called 1 set. The participants were asked to practice 6 sets/day, 5 days/week (Monday-Friday) for week 1-4, and increased duration to 8 sets/day, 5 days/week for week 5-8.
Study: NCT00882193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alpha 2a
Description: Peginterferon alpha 2a 180mcg/0.5ml by subcutaneous injection weekly for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin 200mg - weight based, 1000 - 1200 mg/day for body weight \< or \> 75mg in 2 divided doses
Study: NCT03849859

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Single plastic stent
Description: Deployment of single plastic stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Multiple plastic stents
Description: Deployment of multiple plastic stents
Study: NCT04639609

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Characterization of Neuromuscular Function and Fatigue
Description: at inclusion

Intervention type: OTHER
Group type: OTHER
Intervention: Characterization of Neuromuscular Function and Fatigue
Description: at inclusion
Study: NCT04475679

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adhese Universal DC
Description: Adhese Universal DC, a dental adhesive, will be used in conjunction with the luting cement Variolink Esthetic to bond indirect restorations to the tooth surface

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Adhese Universal
Description: Adhese Universal, a dental adhesive, will be used in conjunction with the luting cement Variolink Esthetic to bond indirect restorations to the tooth
Study: NCT03060447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vesatolimod
Description: Tablets Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablets Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ART
Description: ART regimens administered in accordance with their prescribing information. The following agents are allowed as part of the ART regimen: nucleoside reverse transcriptase inhibitors, raltegravir, dolutegravir (DTG), rilpivirine, and maraviroc.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ART
Description: ART regimens administered in accordance with their prescribing information. The following agents are allowed as part of the ART regimen: nucleoside reverse transcriptase inhibitors, raltegravir, dolutegravir (DTG), rilpivirine, and maraviroc.